Abstract:Cyclin Dependent Kinase 9 (CDK9) is one of the most important transcription regulatory members of the CDK family. In conjunction with its main cyclin partner—Cyclin T1, it forms the Positive Transcription Elongation Factor b (P-TEFb) whose primary function in eukaryotic cells is to mediate the positive transcription elongation of nascent mRNA strands, by phosphorylating the S2 residues of the YSPTSPS tandem repeats at the C-terminus domain (CTD) of RNA Polymerase II (RNAP II). To aid in this process, P-TEFb also simultaneously phosphorylates and inactivates a number of negative transcription regulators like 5,6-dichloro-1-β-D-ribofuranosylbenzimidazole (DRB) Sensitivity-Inducing Factor (DSIF) and Negative Elongation Factor (NELF). Significantly enhanced activity of CDK9 is observed in multiple cancer types, which is universally associated with significantly shortened Overall Survival (OS) of the patients. In these cancer types, CDK9 regulates a plethora of cellular functions including proliferation, survival, cell cycle regulation, DNA damage repair and metastasis. Due to the extremely critical role of CDK9 in cancer cells, inhibiting its functions has been the subject of intense research, resulting the development of multiple, increasingly specific small-molecule inhibitors, some of which are presently in clinical trials. The search for newer generation CDK9 inhibitors with higher specificity and lower potential toxicities and suitable combination therapies continues. In fact, the Phase I clinical trials of the latest, highly specific CDK9 inhibitor BAY1251152, against different solid tumors have shown good anti-tumor and on-target activities and pharmacokinetics, combined with manageable safety profile while the phase I and II clinical trials of another inhibitor AT-7519 have been undertaken or are undergoing. To enhance the effectiveness and target diversity and reduce potential drug-resistance, the future of CDK9 inhibition would likely involve combining CDK9 inhibitors with inhibitors like those against BRD4, SEC, MYC, MCL-1 and HSP90.

CDK8 as a therapeutic target for cancers and recent developments in discovery of CDK8 inhibitors

Unveiling the impact of CDK8 on tumor progression: mechanisms and therapeutic strategies

Targeting CDK7 in oncology: The avenue forward.

Angel or Devil ? - CDK8 as the new drug target

Cyclin-dependent Kinase Inhibition and Its Intersection with Immunotherapy in Breast Cancer: More Than CDK4/6 Inhibition

Recent Developments in the Biology and Medicinal Chemistry of CDK9 Inhibitors: an Update.

Targeting cyclin-dependent kinase 9 in cancer therapy

Discovery of a Novel and Potent Cyclin-Dependent Kinase 8/19 (CDK8/19) Inhibitor for the Treatment of Cancer

CDK9: A Comprehensive Review of Its Biology, and Its Role as a Potential Target for Anti-Cancer Agents

CDK9 inhibitors in cancer research

Current progress and novel strategies that target CDK12 for drug discovery.

Discovery of Potent, Selective, and Orally Bioavailable Small-Molecule Inhibitors of CDK8 for the Treatment of Cancer

Transcriptional cyclin-dependent kinases: Potential drug targets in cancer therapy

Targeting CDK9 for Anti-Cancer Therapeutics

A Patent Review of Selective CDK9 Inhibitors in Treating Cancer

Recent Progress in Development of Cyclin-Dependent Kinase 7 Inhibitors for Cancer Therapy

Targeting CDK9 with Selective Inhibitors or Degraders in Tumor Therapy: an Overview of Recent Developments

Advances in research on a novel antitumor target CDK9 and its inhibitors

Development of CDK12 as a Cancer Therapeutic Target and Related Inhibitors

Heterocyclic Compounds as CDK9 Inhibitors: Structural Diversity, Mechanism of Action, and Therapeutic Potential in Cancer and Beyond

Recent progress of cyclin-dependent kinase inhibitors as potential anticancer agents.